Repare Therapeutics Inc. (RPTX) Revenue History
Annual and quarterly revenue from 2018 to present
RPTX Revenue Over Time (2018–2024)
RPTX Revenue Growth History
3 of 4 years with positive growth- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- +5529.6%
- FY2022 revenue growth
- +1634.6%
- FY2023 revenue growth
- -61.2%
- FY2024 revenue growth
- +4.6%
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $11.6M | — |
| Q2 2025 | $250K | -76.7% |
| Q1 2025 | $0 | -100.0% |
| Q4 2024 | $0 | -100.0% |
| Q3 2024 | $0 | -100.0% |
| Q2 2024 | $1.1M | -96.5% |
| Q1 2024 | $52.4M | +822.9% |
| Q4 2023 | $13.0M | -28.3% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown
RPTX's revenue distribution by segment and geography
By Geography
RPTX Revenue Analysis (2018–2024)
Current Revenue & Growth
As of June 28, 2026, Repare Therapeutics Inc. (RPTX) generated trailing twelve-month (TTM) revenue of $11.9 million. The most recent quarter (Q3 2025) recorded $11.6 million in revenue, up 4548.0% sequentially.
Historical Growth Trajectory
RPTX's historical revenue data shows a 3-year CAGR of +91.6%. Repare Therapeutics Inc.'s highest annual revenue of $131.8 million was recorded in 2022.
Peer Comparison
Compared to Healthcare sector peers — including ACLX (-79.4% YoY), and KYMR (-12.6% YoY). Compare RPTX vs ACLX →
RPTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RPTXCurrent | $12M | - | - | -174.9% | |
 ACLX | $22M | -79.4% | - | -1135.6% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% |
RPTX Historical Revenue Data (2018–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $53.5M | +4.6% | $40.1M | 75.0% | $-93,523,000 | -174.9% |
| 2023 | $51.1M | -61.2% | $37.9M | 74.1% | $-116,224,000 | -227.3% |
| 2022 | $131.8M | +1634.6% | $15.1M | 11.5% | $-19,796,000 | -15.0% |
| 2021 | $7.6M | +5529.6% | $-80,254,000 | -1056.0% | $-108,660,000 | -1429.7% |
| 2020 | $135K | - | $-38,640,000 | -28622.2% | $-54,302,000 | -40223.7% |
| 2019 | $0 | - | $-968,000 | - | $-25,811,000 | - |
| 2018 | $0 | - | $-407,000 | - | $-12,820,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RPTX — Frequently Asked Questions
Quick answers to the most common questions about buying RPTX stock.
Is RPTX's revenue growth accelerating or slowing?
RPTX TTM revenue: $12M. YoY growth: N/A. 5-year CAGR: N/A.
What is RPTX's revenue history from 2018 to 2026?
Repare Therapeutics Inc. (RPTX) revenue history spans 2018 to 2026. TTM revenue as of 2026 is $12M, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is RPTX's long-term revenue growth rate (CAGR)?
Repare Therapeutics Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for RPTX.
Why does RPTX's quarterly revenue fluctuate?
RPTX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Repare Therapeutics Inc.'s revenue data from 2018 to 2026 shows full historical quarterly detail on this page.
How is RPTX's revenue distributed by segment?
RPTX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does RPTX's revenue compare to industry peers?
Repare Therapeutics Inc. (RPTX) with TTM revenue of $12M and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.